Zimmer Biomet Holdings Inc (NYSE:ZBH) Shares Acquired by Steward Partners Investment Advisory LLC

Share on StockTwits

Steward Partners Investment Advisory LLC grew its holdings in Zimmer Biomet Holdings Inc (NYSE:ZBH) by 12.1% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,135 shares of the medical equipment provider’s stock after buying an additional 231 shares during the quarter. Steward Partners Investment Advisory LLC’s holdings in Zimmer Biomet were worth $251,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of ZBH. BlackRock Inc. increased its stake in Zimmer Biomet by 3.2% in the 1st quarter. BlackRock Inc. now owns 16,474,877 shares of the medical equipment provider’s stock valued at $2,103,841,000 after purchasing an additional 509,160 shares in the last quarter. OppenheimerFunds Inc. increased its stake in Zimmer Biomet by 7.9% in the 1st quarter. OppenheimerFunds Inc. now owns 3,156,333 shares of the medical equipment provider’s stock valued at $403,063,000 after purchasing an additional 231,307 shares in the last quarter. Geode Capital Management LLC increased its stake in Zimmer Biomet by 8.4% in the 4th quarter. Geode Capital Management LLC now owns 2,641,717 shares of the medical equipment provider’s stock valued at $273,516,000 after purchasing an additional 205,532 shares in the last quarter. Primecap Management Co. CA increased its stake in Zimmer Biomet by 29.4% in the 1st quarter. Primecap Management Co. CA now owns 2,463,720 shares of the medical equipment provider’s stock valued at $314,617,000 after purchasing an additional 559,370 shares in the last quarter. Finally, Boston Partners increased its stake in Zimmer Biomet by 61.9% in the 1st quarter. Boston Partners now owns 1,754,479 shares of the medical equipment provider’s stock valued at $224,047,000 after purchasing an additional 670,501 shares in the last quarter. 87.89% of the stock is owned by institutional investors and hedge funds.

ZBH has been the subject of several research analyst reports. Wells Fargo & Co raised their price objective on Zimmer Biomet from $143.00 to $150.00 and gave the company an “outperform” rating in a research note on Monday, July 29th. Jefferies Financial Group raised their price objective on Zimmer Biomet from $150.00 to $167.00 and gave the company a “buy” rating in a research note on Monday, July 29th. They noted that the move was a valuation call. Needham & Company LLC raised Zimmer Biomet from a “buy” rating to a “strong-buy” rating and raised their price objective for the company from $146.00 to $155.00 in a research note on Wednesday, April 24th. Robert W. Baird raised Zimmer Biomet from a “neutral” rating to an “outperform” rating and raised their price objective for the company from $132.00 to $154.00 in a research note on Monday, July 29th. Finally, Argus raised Zimmer Biomet from a “hold” rating to a “buy” rating and set a $160.00 price objective for the company in a research note on Monday. Two equities research analysts have rated the stock with a sell rating, six have issued a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $141.56.

Zimmer Biomet stock opened at $138.17 on Wednesday. The company has a quick ratio of 0.56, a current ratio of 1.19 and a debt-to-equity ratio of 0.58. The business’s fifty day moving average is $126.39. The stock has a market capitalization of $28.40 billion, a P/E ratio of 18.09, a price-to-earnings-growth ratio of 2.47 and a beta of 1.15. Zimmer Biomet Holdings Inc has a fifty-two week low of $96.99 and a fifty-two week high of $140.53.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings results on Friday, July 26th. The medical equipment provider reported $1.93 earnings per share for the quarter, topping the consensus estimate of $1.91 by $0.02. The company had revenue of $1.99 billion during the quarter, compared to the consensus estimate of $1.98 billion. Zimmer Biomet had a positive return on equity of 13.40% and a negative net margin of 4.56%. Zimmer Biomet’s revenue was down .9% compared to the same quarter last year. During the same quarter last year, the business posted $1.92 earnings per share. Research analysts anticipate that Zimmer Biomet Holdings Inc will post 7.82 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which was paid on Wednesday, July 31st. Shareholders of record on Friday, June 28th were given a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a yield of 0.69%. The ex-dividend date of this dividend was Thursday, June 27th. Zimmer Biomet’s payout ratio is 12.57%.

In other Zimmer Biomet news, insider Sang Yi sold 426 shares of the firm’s stock in a transaction on Friday, May 24th. The stock was sold at an average price of $114.88, for a total transaction of $48,938.88. Following the completion of the transaction, the insider now owns 1,457 shares of the company’s stock, valued at $167,380.16. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.72% of the company’s stock.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates through four segments: Spine, less Asia Pacific; Office Based Technologies; Craniomaxillofacial and Thoracic; and Dental.

Featured Article: Understanding Options Trading

Institutional Ownership by Quarter for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

EJF Capital LLC Lowers Stake in Sandy Spring Bancorp Inc.
EJF Capital LLC Lowers Stake in Sandy Spring Bancorp Inc.
EJF Capital LLC Buys New Position in Radian Group Inc
EJF Capital LLC Buys New Position in Radian Group Inc
EJF Capital LLC Has $7.26 Million Position in Rhinebeck Bancorp Inc
EJF Capital LLC Has $7.26 Million Position in Rhinebeck Bancorp Inc
EJF Capital LLC Buys Shares of 402,288 Mainstreet Bank Common Stock
EJF Capital LLC Buys Shares of 402,288 Mainstreet Bank Common Stock
EJF Capital LLC Grows Stock Position in First Savings Financial Group Inc
EJF Capital LLC Grows Stock Position in First Savings Financial Group Inc
SB Financial Group Inc  Shares Bought by EJF Capital LLC
SB Financial Group Inc Shares Bought by EJF Capital LLC


© 2006-2019 Ticker Report